A Phase II, Single-Arm Trial of Naked Epratuzumab, an Anti-CD22 Humanized Antibody, in Patients with Waldenström's Macroglobulinemia The primary objective is to evaluate the efficacy of epratuzumab in WM as determined by the response rate for patients with partial or complete responses.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase I/II Study of Immunotherapy with Subcutaneous Administered Veltuzumab (hA20) in Patients with CD20+ Non-Hodgkin's Lymphoma or Chronic Lyphocytic Leukemia To determine if a subcutaneous dosing schedule of veltuzumab can be established in NHL or CLL paitent and to confirm safety and efficacy of veltuzumab that was previously established when administered...

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase Ib/II Study of Fractionated 90-Y-hPAM4 Plus Gemcitabine in Patients with Previously Untreated Advanced Pancreatic Cancer To evaluate the feasibility, safety and tolerability of this treatment regimen, and to determine acceptable 90-Y dose and gemcitabine dosing for use with this approach.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Studyof Epratuzumab in Patients with Active Systemic Lupus Erythematosus The primary study objective is to demonstrate that epratuzumab is effective for improvement of the signs and symptoms of SLE.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Estudio en fase III, multicéntrico, doble-ciego, aleatorizado, controlado con placebo de Epratuzumab en pacientes con crisis agudas severas de Lupus Eritematoso Sistémico excluyendo los sistemas renal o neurológico El objetivo principal del estudio es demostrar que epratuzumab es eficaz para el tratamiento de la exacerbación aguda de lupus.

• Pays Aucun
• Organes Aucun
• Spécialités Aucune

Radioimmunotherapy with 90Y-Clivatizumab Tetraxetan plus Low Dose Gemcitabine versus Placebo plus Low-Dose Gemcitabine Overall Survival (OS)

• Pays Aucun
• Organes Aucun
• Spécialités Aucune